Remove Clinical Development Remove Download Remove Pharmaceuticals
article thumbnail

FSP Engagements Continue to Gain Popularity, Drive Success

PPD

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

article thumbnail

Reimagining CRO Partnerships: The Emerging Preference for Midsize Organizations

Conversations in Drug Development Trends

Worldwide Clinical Trials recently conducted a comprehensive research study, where we included 140 key industry-decision makers from biotech and pharmaceutical companies of all sizes. Discover how Worldwide is positioned to meet your needs with agility, expertise, and a truly personalized approach.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel

The Pharma Data

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. Dr. Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc. SAN JOSE, Calif. ,

article thumbnail

CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients

The Pharma Data

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). ET ) to discuss the results and next steps in clinical development of BI-1206. About CASI Pharmaceuticals. CASI Pharmaceuticals, Inc. SOURCE CASI Pharmaceuticals, Inc.

article thumbnail

CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

The Pharma Data

17, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. “Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. About CNS Pharmaceuticals, Inc. View original content to download multimedia: [link].

article thumbnail

Navigating the Global Clinical Landscape: CTA or IND for Your First-in-Human Study?

Conversations in Drug Development Trends

When conducting first-in-human (FIH) clinical trials, small to midsize pharmaceutical and biotechnology companies are faced with several crucial choices that can shape the trajectory of their drug development pathway. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

article thumbnail

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track DesignationPhase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month

The Pharma Data

Drugs developed under the Fast Track program are afforded increased access to FDA staff and may qualify for other programs to further expedite their clinical development, such as priority review and accelerated approval. A preprint supporting Brilacidin’s COVID-19 treatment potential can be downloaded at the link below.